

May 16, 2007 – News Release

Affectis Pharmaceuticals AG Further Strengthens Management Team

Munich, Germany, -- Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs against depression and schizophrenia, announced today that it has further strengthened its management team by appointing Jesper P. Wiklund as Chief Business Officer and Head of Finance. In addition, Affectis is announcing changes in the Company's Supervisory Board.

"We are very happy to welcome Jesper Wiklund as CBO," said Herbert Stadler, CEO of Affectis. "He is bringing more than 15 years of experience as a business development specialist in the life science industry and, specifically, in the CNS area."

Prior to joining Affectis, Jesper Wiklund was Senior Vice President Business Development of the Pharmaceuticals Division of Evotec OAI AG and a member of Evotec's Executive Committee. Before joining Evotec, he served in Business Development and sales roles with DeveloGen, Elan Corporation and Wyeth Pharmaceuticals. Jesper Wiklund also was co-founder of eLabsEurope. He earned a MBA at Harvard Business School and a BSc in Biology from St. Mary's College of California.

"Affectis' projects have found considerable interest in the pharmaceutical industry," said Jesper Wiklund, "we will now start exploring licensing and partnering opportunities."

Following the resignation of Prof Florian Holsboer as Chairman of the Company's Supervisory Board, Dr Joachim Rothe took over as Chairman while Dr Domenico (Dinko) Valerio was appointed Vice Chairman. In June, Alex Martin, currently Chief Operating Officer of New York based Intercept Pharmaceuticals will join the Supervisory Board. Martin worked, among others, as Chief Financial Officer at BioXell (BXLN.S), and as Vice President, Global Business Development and Licensing at Novartis Pharma AG.

"I wish to thank Florian Holsboer for his long lasting commitment and his important contributions to the company, and I am happy that he will continue to serve as member of the Company's Scientific Advisory Board," Joachim Rothe said.

Contact for Affectis Pharmaceuticals AG:

Sabina van den Brandt
Kraepelinstrasse 2
D-80804 Munich, Germany
Tel: +49 (0)89 - 306 22 - 591
Fax: +49 (0)89 - 306 22 - 370
Email: contact@affectis.com
www.affectis.com

Notes to Editors

About Affectis Pharmaceuticals AG:

Affectis is a biopharmaceutical company implementing novel concepts for the treatment of mental disorders, especially depression and schizophrenia. The Company has unique capabilities to discover and develop drugs based on pioneering findings in the field of mental disorders. These drugs address the increasing need for more comprehensive and faster-acting antidepressants with fewer side effects. Affectis started operations in November 2003 as a spin-off from the renowned Max-Planck-Institute of Psychiatry, a world leader in the field of psychiatric research. A strong team of executives and scientists with long-term industry experience contribute to Affectis' progress. The Company raised its third round of venture financing in October 2006, led by AESCAP Venture. Affectis is based in Munich, Germany.

www.affectis.com